Obesità e complicazioni cardiovascolari: rischi, soluzioni e sviluppi clinici
Settembre 24 @ 11:30 AM - 12:30 PM
Durante l’incontro verranno fornite informazioni generali sulle alterazioni metaboliche, in particolare l’obesità, come fattore di rischio per l’insorgenza di malattie cardiovascolari. Partendo da definizioni generali, si intendono condividere informazioni sui metodi diagnostici e sugli approcci clinici per la gestione del paziente e offrire spunti di riflessione sull’ importanza di diagnosi tempestive. Verranno infine forniti aggiornamenti sugli approcci innovativi volti a migliorare la qualità della vita dei soggetti coinvolti evidenziando l’importanza della scelta di trattamenti adeguati nella prevenzione di complicazioni a lungo termine.
A chi si rivolge
Il corso è rivolto a esperti del settore e non e, in particolare, a chi ha interesse a saperne di più sull’insieme dei fattori di rischio che compromettono la nostra salute.
Cosa impariamo dal webinar
- Come individuare un target terapeutico
- Come costruire una linea di sviluppo pre-clinico
- Come testare una molecola innovativa in modelli pre-clinici
Docente
- Riccardo Panella got his master degree in Biotechnology as well as his Ph.D. in Molecular Oncology in at the University of Perugia in Italy after which he was awarded a post-doctoral fellowship from the Marie Curie Foundation in 2014. He worked for six years as a Post-Doctoral fellow at (Beth Israel Deaconess Medical Center Cancer Institute / Harvard Medical School Cancer Center) (cancer center of the Harvard Medical School). Riccardo has focused his entire career on translational medicine, with the main goal of developing new treatment options and new therapeutic approaches to disease. His expertise lies in the application of non-coding RNA as both a therapeutic target and as cutting-edge technology for developing new therapeutic paradigms. He is now serving as Associate Professor at the Center for RNA medicine in the Copenhagen campus of Aalborg University in Denmark and he is leading a team that is currently investigating the role of non-coding RNAs in metabolic homeostasis and how it affects human metabolism. In parallel to his academic activity, he is also one of the co-founders and CSO of Resalis Therapeutic, a biotech company aim developing an innovative RNA based approach for the cure of obesity and non alcoholic liver disease.
